{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-265717","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.673682+00:00","generated_at":"2026-06-09T06:00:03.832992+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Viridian Therapeutics announces new CEO, $185M private placement, next-gen FcRn inhibitors","bullets":["Stephen Mahoney appointed President and CEO, succeeds Scott Myers. Base salary $650k, 55% bonus target, option for 1.26M shares.","$185M private placement: 8.79M shares at $12.38, plus 92,312 convertible preferred shares. Closing expected Nov 1, 2023.","Discloses preclinical FcRn inhibitors VRDN-006 and VRDN-008; first IND filing by year-end 2024. Targets autoimmune diseases.","TED pipeline: subcutaneous program selection by end 2023; VRDN-001 THRIVE Phase 3 active TED readout mid-2024.","Thomas Beetham appointed COO; base salary $500k, 45% bonus target, option for 474k shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-265717","json":"https://secwatch.observer/filing/0001193125-23-265717.json","markdown":"https://secwatch.observer/filing/0001193125-23-265717.md","text":"https://secwatch.observer/filing/0001193125-23-265717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/d567471d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T06:00:03.832992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8711e2dc07","claim":"Stephen Mahoney was appointed as Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"Mr. Mahoney was also appointed to the Company’s Board of Directors (the “Board”) as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f062df71c6","claim":"Stephen Mahoney was appointed as President and Chief Executive Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On October 30, 2023, the Company announced the appointment of Stephen Mahoney as the Company’s President and Chief Executive Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"42ded7cf9012418fcd7128efc44e2a28bcf105e6","claim":"Viridian Therapeutics, Inc.\\DE entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $185 million (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, Viridian Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $185 million"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}